Bank of New York Mellon Corp Buys 20,385 Shares of IQVIA Holdings Inc. $IQV

Bank of New York Mellon Corp raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,023,985 shares of the medical research company’s stock after buying an additional 20,385 shares during the quarter. Bank of New York Mellon Corp’s holdings in IQVIA were worth $194,496,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IQV. Root Financial Partners LLC purchased a new position in IQVIA during the third quarter valued at $43,000. Asset Dedication LLC lifted its stake in IQVIA by 224.0% during the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 168 shares during the period. Trust Co. of Toledo NA OH bought a new position in IQVIA during the second quarter valued at approximately $39,000. J.Safra Asset Management Corp lifted its holdings in shares of IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after buying an additional 169 shares during the period. Finally, Hemington Wealth Management boosted its position in IQVIA by 43.4% in the third quarter. Hemington Wealth Management now owns 261 shares of the medical research company’s stock worth $49,000 after purchasing an additional 79 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of IQV stock opened at $229.93 on Friday. The stock’s 50-day moving average is $230.94 and its 200 day moving average is $208.19. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The company has a market cap of $39.16 billion, a P/E ratio of 31.54, a PEG ratio of 2.39 and a beta of 1.36.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the prior year, the business posted $2.84 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Truist Financial lifted their price target on shares of IQVIA from $265.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Barclays set a $230.00 price target on shares of IQVIA in a report on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. UBS Group upped their target price on shares of IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, Evercore ISI raised their price target on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $251.06.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.